121 related articles for article (PubMed ID: 6319700)
1. Resorcinol congeners of dopamine derived from benzocycloheptene and indan.
Cannon JG; Pease JP; Hamer RL; Ilhan M; Bhatnagar RK; Long JP
J Med Chem; 1984 Feb; 27(2):186-9. PubMed ID: 6319700
[TBL] [Abstract][Full Text] [Related]
2. Conformationally restricted congeners of dopamine derived from octahydrobenzo[g]quinoline and octahydrobenzo[f]quinoline.
Cannon JG; Hamer RL; Ilhan M; Bhatnagar RK; Long JP
J Med Chem; 1984 Feb; 27(2):190-5. PubMed ID: 6694167
[TBL] [Abstract][Full Text] [Related]
3. Comparison of biological effects of N-alkylated congeners of beta-phenethylamine derived from 2-aminotetralin, 2-aminoindan, and 6-aminobenzocycloheptene.
Cannon JG; Perez JA; Pease JP; Long JP; Flynn JR; Rusterholz DB; Dryer SE
J Med Chem; 1980 Jul; 23(7):745-9. PubMed ID: 7190613
[TBL] [Abstract][Full Text] [Related]
4. Catechol derivatives of 6-aminobenzocycloheptene: assessment of dopaminergic effects.
Cannon JG; Pease JP; Long JP; Flynn J
J Med Chem; 1984 Jul; 27(7):922-3. PubMed ID: 6737435
[TBL] [Abstract][Full Text] [Related]
5. Structure activity relationships of resorcinol substituted ring systems.
Ilhan M; Long JP; Flynn J; Bhatnagar R; Cannon JG
Arch Int Pharmacodyn Ther; 1984 Sep; 271(1):22-32. PubMed ID: 6093720
[TBL] [Abstract][Full Text] [Related]
6. 5,7-Dihydroxy-2-aminotetralin derivatives: synthesis and assessment of dopaminergic and adrenergic actions.
Cannon JG; Brubaker AN; Long JP; Flynn JR; Verimer T; Harnirattisai P; Costall B; Naylor RJ; Nohria V
J Med Chem; 1981 Feb; 24(2):149-53. PubMed ID: 7205882
[TBL] [Abstract][Full Text] [Related]
7. Assessment of a potential dopaminergic prodrug moiety in several ring systems.
Cannon JG; Furlano DC; Dushin RG; Chang YA; Baird SR; Soliman LN; Flynn JR; Long JP; Bhatnagar RK
J Med Chem; 1986 Oct; 29(10):2016-20. PubMed ID: 3761320
[TBL] [Abstract][Full Text] [Related]
8. Conformationally restricted congeners of dopamine derived from 2-aminoindan.
Cannon JG; Perez JA; Bhatnagar RK; Long JP; Sharabi FM
J Med Chem; 1982 Dec; 25(12):1442-6. PubMed ID: 7154005
[TBL] [Abstract][Full Text] [Related]
9. Monophenolic 2-(dipropylamino)indans and related compounds: central dopamine-receptor stimulating activity.
Hacksell U; Arvidsson LE; Svensson U; Nilsson JL; Wikström H; Lindberg P; Sanchez D; Hjorth S; Carlsson A; Paalzow L
J Med Chem; 1981 Apr; 24(4):429-34. PubMed ID: 7265130
[TBL] [Abstract][Full Text] [Related]
10. 1-(Aminomethyl)-6,7-dihydroxytetralin derivatives: synthesis and assessment of dopamine-like effects.
Cannon JG; Perez Z; Long JP; Ilhan M
J Med Chem; 1983 Jun; 26(6):813-6. PubMed ID: 6854584
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and dopaminergic activity of some halogenated mono- and dihydroxylated 2-aminotetralins.
Weinstock J; Gaitanopoulos DE; Oh HJ; Pfeiffer FR; Karash CB; Venslavsky JW; Sarau HM; Flaim KE; Hieble JP; Kaiser C
J Med Chem; 1986 Sep; 29(9):1615-27. PubMed ID: 2875183
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and pharmacological evaluation of aromatic dihydroxylated spiro[indan-1,3'-pyrrolidine] and spiro[indan-2,2'-pyrrolidine] derivatives.
Sommerville R; Rosenberg HE; Crooks PA
J Pharm Sci; 1985 May; 74(5):553-5. PubMed ID: 4020632
[TBL] [Abstract][Full Text] [Related]
13. 2-Amino-4,7-dimethoxyindan derivatives: synthesis and assessment of dopaminergic and cardiovascular actions.
Sindelar RD; Mott J; Barfknecht CF; Arneric SP; Flynn JR; Long JP; Bhatnagar RK
J Med Chem; 1982 Jul; 25(7):858-64. PubMed ID: 6125597
[TBL] [Abstract][Full Text] [Related]
14. Conformational analysis of 2-aminoindans and 2-(aminomethyl)indans in relation to their central dopaminergic effects and a dynamic dopamine receptor concept.
Wikström H; Lii JH; Allinger NL
J Med Chem; 1987 Jul; 30(7):1115-20. PubMed ID: 3599018
[TBL] [Abstract][Full Text] [Related]
15. Dopaminergic structure-activity relationships of 2-aminoindans and cardiovascular action and dopaminergic activity of 4-hydroxy, 5-methyl, 2-di-n-propylaminoindan (RD-211).
Ma SX; Long JP; Flynn JR; Leonard PA; Cannon JG
J Pharmacol Exp Ther; 1991 Feb; 256(2):751-6. PubMed ID: 1671601
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships of dopamine agonists.
Cannon JG
Annu Rev Pharmacol Toxicol; 1983; 23():103-29. PubMed ID: 6347047
[No Abstract] [Full Text] [Related]
17. Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors.
Brown RA; Dixon J; Farmer JB; Hall JC; Humphries RG; Ince F; O'Connor SE; Simpson WT; Smith GW
Br J Pharmacol; 1985 Jul; 85(3):599-608. PubMed ID: 2862944
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of 2-(alkylamino)-5,6- and -6,7-dihydroxy-3,4-dihydroquinazolines and evaluation as potential dopamine agonists.
Grosso JA; Nichols DE; Kohli JD; Glock D
J Med Chem; 1982 Jun; 25(6):703-8. PubMed ID: 7097723
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of dopaminergic and alpha adrenergic activities of TL-99 in peripheral tissues in vitro.
Ilhan M; Long JP; Abou Zeit-Har MS; Cannon JG
Arch Int Pharmacodyn Ther; 1986 Jan; 279(1):17-28. PubMed ID: 3008675
[TBL] [Abstract][Full Text] [Related]
20. Dopamine receptor agonistic activities of R- and S-enantiomers of 4-hydroxy-2-di-n-propylaminoindan in cat hearts.
Ilhan M; Flynn JR; Long JP; Bhatnagar RK; Cannon JG
J Pharm Pharmacol; 1985 May; 37(5):364-5. PubMed ID: 2862251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
